Home・Akciju saraksts・Krystal Biotech Inc

Krystal Biotech Inc

Slēgts

SektorsVeselības aprūpe

322.67 0.11

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

319.45

Max

327.74

Galvenie mērījumi
By Trading Economics
Ienākumi	-1.2M 55M
Pārdošana	2.9M 119M
P/E Sektora vidējais	45.697 68.51
EPS	1.79
Peļņas marža	45.938
Darbinieki	295
EBITDA	2.9M 66M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+23.76% upside

Dividendes
By Acuity
Nākamie ieņēmumi	2026. g. 2. nov.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-1.1B 9.3B
Iepriekšējā atvēršanas cena	322.56
Iepriekšējā slēgšanas cena	322.67

Ziņu noskaņojums

By Acuity

86%

14%

323 / 340 Rangs Healthcare

Krystal Biotech Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 5. aug. 19:52 UTC

Krystal Biotech Inc shares are lower today, breaking a trend of higher closes. Broader market sentiment is cautious following ADP's weak employment report.

2026. g. 4. aug. 20:04 UTC

News

Citigroup raised its price target on Krystal Biotech to $386, contributing to upward movement in shares despite earlier session pullbacks.

2026. g. 3. aug. 23:06 UTC

Krystal Biotech Inc shares are higher in after-market hours, recovering from an earlier dip. Broader market sentiment improved following stronger-than-expected economic data.

2026. g. 31. jūl. 23:06 UTC

Krystal Biotech Inc is trading lower in after-market hours amid volatility, with no specific news identified to explain the movement.

2026. g. 30. jūl. 19:39 UTC

Krystal Biotech Inc shares are higher today, maintaining gains since Wednesday's close. The stock remains above its 20-day moving average despite a slight pullback.

2026. g. 29. jūl. 20:04 UTC

Krystal Biotech shares are lower amid a broader market decline, influenced by significant drops in major U.S. stocks ahead of the Federal Reserve's announcement.

2026. g. 28. jūl. 20:03 UTC

Event

Social Media

Krystal Biotech Inc. shares rise amid strong Biotechnology sector gains and positive social media discussions, with Q2 FY2026 earnings expected on August 3.

2026. g. 27. jūl. 22:02 UTC

Social Media

Shares of Krystal Biotech are lower in after-market hours, despite discussions of potential catalysts and an upcoming earnings report on August 3.

2026. g. 24. jūl. 19:11 UTC

Krystal Biotech Inc shares are higher today, despite broader market weakness. The stock has seen increased trading activity since Thursday's close.

2026. g. 23. jūl. 10:01 UTC

Krystal Biotech Inc shares are higher in pre-market hours, following a slight after-market increase on Wednesday. No specific news was identified for this movement.

2026. g. 22. jūl. 19:26 UTC

Krystal Biotech Inc shares are lower today amid a broader market decline, with no specific company news identified to explain the movement.

2026. g. 21. jūl. 18:36 UTC

News

Social Media

Krystal Biotech Inc shares are lower today amid trading volatility, despite a planned inclusion in the S&P MidCap 400 on July 24.

2026. g. 20. jūl. 21:21 UTC

News

Krystal Biotech Inc. will replace Taylor Morrison in the S&P MidCap 400 on July 24, 2026. The stock is lower in after-hours trading.

Salīdzinājums

Cenas izmaiņa

Krystal Biotech Inc Prognoze

Cenas mērķis

By TipRanks

23.76% augšup

Prognoze 12 mēnešiem

Vidējais 403.2 USD 23.76%

Augstākais 474 USD

Zemākais 361 USD

Pamatojoties uz 6 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Krystal Biotech Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

6 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 6 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Krystal Biotech Inc — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

323 / 340 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Krystal Biotech Inc

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.